We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Biogen Inc | LSE:0R1B | London | Ordinary Share | BIOGEN INC ORD SHS |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 9.84B | 1.16B | 8.0132 | 23.51 | 40.23B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
18:40:51 | O | 2 | 188.80 | USD |
Date | Time | Source | Headline |
---|---|---|---|
09/10/2024 | 12:30 | UKREG | Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab.. |
08/10/2024 | 12:30 | UKREG | New Higher Dose Nusinersen Efficacy and Safety Data Presented at World.. |
24/9/2024 | 06:00 | UKREG | UCB and Biogen Announce Positive Topline Results From Phase 3 Study of.. |
12/9/2024 | 12:30 | UKREG | Biogen Board Appoints Two New Independent Directors |
04/9/2024 | 12:30 | UKREG | Biogen Announces Positive Topline Results from Study of Higher Dose Regimen.. |
30/7/2024 | 22:15 | UKREG | New Clinical Data Demonstrates Three Years of Continuous Treatment with.. |
30/7/2024 | 12:30 | UKREG | Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based.. |
26/7/2024 | 12:20 | UKREG | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in.. |
06/3/2024 | 12:30 | UKREG | New Biomarker Data Add Further Evidence Supporting the Potential Benefit of.. |
04/3/2024 | 21:15 | UKREG | Biogen Highlights New Data at the International Conference on Alzheimer’s.. |
Biogen (0R1B) Share Charts1 Year Biogen Chart |
|
1 Month Biogen Chart |
Intraday Biogen Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions